Vaxart stock price forecast has been volatile

Vaxart stock price forecast has been volatile, with recent trading around $0.65–$0.72 per share. Analysts tracking biotech microcaps note market sentiment hinges on upcoming Phase 2 clinical trial updates. Short-term models suggest potential 8–12% swings based on news flow. On a more encouraging note the company has added US$61m to its market cap in just the last 7 days, so let's see if we can determine what's driven the three-year loss for shareholders. There are 127 funds or institutions reporting positions in Vaxart. This is an increase of 5 owner(s) or 4.10% in the last quarter. Average portfolio weight of all funds dedicated to VXRT is 0.03%, an increase of 348.03%. Total shares owned by institutions increased in the last three months by 176.80% to 56,133K shares. The put/call ratio of VXRT is 0.12, indicating a bullish outlook. The current Vaxart stock price forecast benefits from sector-wide biotech ETF inflows, which reached $120M last week—often a precursor to higher bid activity in small-cap names.